Recursion uses AI and machine learning to accelerate drug discovery and development for conditions with high unmet medical needs.
Recursion is a TechBio company that applies artificial intelligence to drug discovery and development. The company was founded on the principle of using cell images to train AI to understand biological space and identify cellular disruptions driving disease, aiming to reduce the high failure rate of traditional drug discovery. The Recursion OS platform integrates data, AI models, and high-performance computing to identify new drug targets and design optimized molecules. This approach has led to a pipeline of potential treatments for aggressive cancers and rare diseases, demonstrating improvements in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. The platform continuously improves through a feedback loop of data generation and model training. Recursion generates and aggregates extensive proprietary biological and chemical datasets, exceeding 50 petabytes, covering phenomics, transcriptomics, proteomics, ADME, and de-identified patient data. Their automated wet lab uses robotics and computer vision to conduct millions of cell experiments weekly, feeding results back into the Recursion OS. They collaborate with partners like NVIDIA to leverage supercomputing for data processing and model training.
Integrations: NVIDIA
Platforms: Web
View full Recursion profile on Tools-Radar | Browse Healthcare tools | Alternatives to Recursion
Tools-Radar is a free directory of 10,000+ AI tools — discover, compare, and choose the right AI software for your needs. Visit tools-radar.com